Kura Oncology, Inc. 8-K

What Happened
Kura Oncology, Inc. announced (8-K filed Jan 29, 2026) that its Board adopted amended and restated bylaws effective January 28, 2026. The A&R Bylaws revise advance-notice procedures for stockholder nominations and proposals, change quorum and voting thresholds, incorporate the SEC’s universal proxy rule, and expand indemnification and procedural rules for meetings and record dates. The full A&R Bylaws were filed as Exhibit 3.1 to the 8-K.

Key Details

• Effective date: January 28, 2026; Board adopted the A&R Bylaws and they are attached to the 8-K.
• Nomination/proposal rules: Stockholders must be record holders at the time of the annual meeting as well as at notice time; additional disclosure, representations and certifications are required from proponents and nominees; substitute nominees are prohibited without timely notice.
• Meeting/voting mechanics: Quorum changed from “majority of outstanding shares” to “majority of voting power” of outstanding shares; default approval standard changed from a majority of shares present to a majority of votes cast (abstentions and broker non‑votes excluded).
• Other notable changes: incorporation of Rule 14a‑19 universal proxy procedures; widened alternative meeting‑date window (now +/-30/ +70 days) for timely notice calculation; expanded indemnification and expense‑advancement provisions; added forum-selection provisions including certain federal courts and a Securities Act forum clause.

Why It Matters
These bylaw changes affect how shareholders can nominate directors and bring proposals, and they change how votes are counted and what constitutes a quorum—potentially making it easier to reach quorum and decide matters based on votes actually cast (not including abstentions). Expanded indemnification and advancement rules strengthen protections for directors and officers. Investors should review the A&R Bylaws (Exhibit 3.1) if they plan to nominate directors, run proxy contests, or engage in litigation involving the company, since procedural, venue and disclosure requirements have been tightened.